Infection, Human Immunodeficiency VirusPhase 2NCT01384734
HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
A Phase 2 study testing BMS-663068 400 mg, BMS-663068 800 mg and BMS-663068 600 mg in people with Infection, Human Immunodeficiency Virus, run by ViiV Healthcare at 54 sites in 10 countries.
Trial summary
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Infection, Human Immunodeficiency Virus
- What is being tested?
- BMS-663068 400 mg, BMS-663068 800 mg and BMS-663068 600 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 254 participants
- Where
- 54 sitesin 10 countries
- Study dates
- 26 Jul 2011to 12 May 2017
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
- Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
- Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 < 0.1 μM
- Cluster of differentiation (CD)4+ T-cell count > 50 cells/mm3
Who cannot join
- History (or evidence at Screening) of genotypic resistance to any component of the study regimen [ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)]
- Certain laboratory and electrocardiogram (ECG) values
Trial locations and contacts
54 sites in 10 countries.
54 sites in 10 countries
United States13 sites
GSK Investigational Site
Atlanta, Georgia, 30312
GSK Investigational Site
Austin, Texas, 78705
GSK Investigational Site
Cincinnati, Ohio, 45267-0405
GSK Investigational Site
Coral Gables, Florida, 33134
GSK Investigational Site
Dallas, Texas, 75246
GSK Investigational Site
Durham, North Carolina, 27710
GSK Investigational Site
Longview, Texas, 75605
GSK Investigational Site
New York, New York, 10008
GSK Investigational Site
Orlando, Florida, 32803
GSK Investigational Site
Philadelphia, Pennsylvania, 19104
GSK Investigational Site
San Francisco, California, 94102
GSK Investigational Site
San Francisco, California, 94115
GSK Investigational Site
Washington D.C., District of Columbia, 20009
Mexico7 sites
GSK Investigational Site
Aguascalientes, 20230
GSK Investigational Site
DF, 14000
GSK Investigational Site
Distrito Federal, 03720
GSK Investigational Site
Guadalajara, Jalisco, 44280
GSK Investigational Site
Mexico City, 3100
GSK Investigational Site
San Luis Potosí City, San Luis Potosí, 78240
GSK Investigational Site
Zapopan, Jalisco, 45170
Peru7 sites
GSK Investigational Site
Iquitos, Loreto, Iqui 01
GSK Investigational Site
Lima, 13
GSK Investigational Site
Lima, 1
GSK Investigational Site
Lima, 32
GSK Investigational Site
Lima, 4
GSK Investigational Site
Lima, Lima 11
GSK Investigational Site
Lima, Lima 31
Argentina6 sites
GSK Investigational Site
Buenos Aires, C1141ACG
GSK Investigational Site
Buenos Aires, C1426EGR
GSK Investigational Site
Ciudad de Buenos Aires, Buenos Aires, C1202ABB
GSK Investigational Site
Córdoba, X5000JJS
GSK Investigational Site
Rosario, Santa Fe Province, 2000
GSK Investigational Site
Rosario, S2000CXP
Germany4 sites
GSK Investigational Site
Berlin, 12157
GSK Investigational Site
Bonn, North Rhine-Westphalia, 53127
GSK Investigational Site
Hamburg, 20099
GSK Investigational Site
München, 80336
Romania4 sites
GSK Investigational Site
Bucharest, 021105
GSK Investigational Site
Constanța, 900709
GSK Investigational Site
Craiova
GSK Investigational Site
Iași, 700116
Russia4 sites
GSK Investigational Site
Saint Petersburg, 190103
GSK Investigational Site
Saint Petersburg, 191167
GSK Investigational Site
Saint Petersburg, 196645
GSK Investigational Site
Smolensk, 214006
South Africa4 sites
GSK Investigational Site
Dundee, KwaZulu-Natal, 3000
GSK Investigational Site
Durban, 4001
GSK Investigational Site
Johannesburg, 2010
GSK Investigational Site
Observatory, Cape Town, 7925
Spain4 sites
GSK Investigational Site
Badalona, 08916
GSK Investigational Site
Barcelona, 08036
GSK Investigational Site
Córdoba, 14004
GSK Investigational Site
Madrid, 28046
About this study
Official title: A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.
Read the detailed description
Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint analysis, then open label. The reference groups is all open-label.
Arms: 5 (4 BMS-663068 treatment groups and 1 reference group)
Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)
- Conditions
- Infection, Human Immunodeficiency Virus
- Being tested
- BMS-663068 400 mg, BMS-663068 800 mg, BMS-663068 600 mg, BMS-663068 1200 mg, Raltegravir 400 mg
- Medical subject headings
- Infections, Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BMS-663068 400 mgDrug
Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
BMS-663068 800 mgDrug
Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
BMS-663068 600 mgDrug
Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
BMS-663068 1200 mgDrug
Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Raltegravir 400 mgDrug
Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Tenofovir 300 mgDrug
Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Ritonavir 100 mgDrug
Tablets, Oral, 100 mg, Once daily, 96 weeks
Atazanavir 300 mgDrug
Capsules, Oral, 300 mg, Once daily, 96 weeks
| Study group | Role | What they receive |
|---|---|---|
| Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir | Experimental | Treatment Group 1 Receives: Drug: BMS-663068 400 mg; Drug: Raltegravir 400 mg; Drug: Tenofovir 300 mg |
| Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir | Experimental | Treatment Group 2 Receives: Drug: BMS-663068 800 mg; Drug: Raltegravir 400 mg; Drug: Tenofovir 300 mg |
| Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir | Experimental | Treatment Group 3 Receives: Drug: BMS-663068 600 mg; Drug: Raltegravir 400 mg; Drug: Tenofovir 300 mg |
| Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir | Experimental | Treatment Group 4 Receives: Drug: BMS-663068 1200 mg; Drug: Raltegravir 400 mg; Drug: Tenofovir 300 mg |
| Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir | Active comparator | Treatment Group 1 (reference arm) Receives: Drug: Raltegravir 400 mg; Drug: Tenofovir 300 mg; Drug: Ritonavir 100 mg; Drug: Atazanavir 300 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24
Percentage of participants with plasma HIV 1 RNA < 50 c/mL at Week 24 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage confidence intervals (CI). Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest. Intent-To-Treat-Exposed (ITT-E) Population includes all randomized participants who received at least one dose of study treatment.
Measured: Week 24
Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety population included all participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week 24 included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 24 visit snapshot window.
Measured: Up to Week 24
Secondary outcomes (15)
Change From Monotherapy Baseline in log10 HIV RNA of the Monotherapy Period
Change from monotherapy Baseline in log10 HIV RNA to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. ITT-E Monotherapy Population comprised of participants that were randomized and participated in the monotherapy sub-study and received at least one dose of FTR Monotherapy. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Measured: Baseline and up to Day 8 of the monotherapy period
Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA
Maximum decrease from monotherapy Baseline in log10 plasma HIV-1 RNA during monotherapy to assess the antiviral activity of temsavir following administration of selected doses of FTR administered orally to HIV-1-infected participants for 7 days. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment. Change from Baseline was calculated as value at indicated time point minus Baseline value. The data for monotherapy nadir has been presented where nadir represents the maximum decrease from Baseline.
Measured: Baseline and up to Day 8 of the monotherapy period
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period
Percentage of participants with plasma HIV 1 RNA < 50 c/mL at Baseline of combination therapy was assessed to evaluate the antiviral activity of four doses of FTR. Baseline of combination therapy was the Day 1 of the combination therapy. Virologic success or failure was determined using the non-missing viral load value at Baseline of combination therapy. The assessment closest to the window target Study Day was used for the analysis. Only those participants with data available at the specified time points were analyzed.
Measured: Up to Day 8 of the monotherapy period
Number of Participants With SAE and Discontinuation Due to AEs During Monotherapy Period
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment.
Measured: Up to Day 8 of the monotherapy period
Change From Monotherapy Baseline in Cluster of Differentiation (CD)4+ and CD8+ T-cell Counts During Monotherapy
Blood was collected and CD4+ and CD8+ cell count assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.
Measured: Baseline and Day 8
Change From Monotherapy Baseline in CD4+ and CD8+ T-cell Proportion During Monotherapy
Blood was collected and CD4+ and CD8+ proportion assessment was done by flow cytometery and was carried out at Baseline (Day 1) to evaluate the immunological activity of multiple doses of FTR. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and the values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants with data available at the specified time points were analyzed.
Measured: Baseline and Day 8
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Primary Study
Percentage of participants with plasma HIV 1 RNA < 50 c/mL at Weeks 48 and 96 using the FDA snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage CI. Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest.
Measured: Weeks 48 and 96
Number of Participants With SAE and Discontinuation Due to AEs During Primary Study
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety Population comprised of participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week X (where X = 48 or 96) included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 48 and 96 visit snapshot window.
Measured: Weeks 48 and 96
Change From Baseline in CD4+ T-cell Count
Blood was collected and CD4+ cell count assessment by flow cytometery was carried out at Baseline (Day 1), Weeks 24, 48 and 96 to evaluate the immunological activity of multiple doses of BMS-663068/GSK3684934. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Measured: Baseline and Weeks 24, 48 and 96
Number of Participants With Newly-emergent Genotypic Substitutions at Week 24
Participants who administered antiretroviral (ARV) with virologic failure (VF) were assessed. Genotypic substitution included assessment of Reverse Transcriptase (RT) substitution, Protease Inhibitor (PI) substitution and Integrase RAL substitution as per International Acquired Immune Deficiency Syndrome (AIDS) Society-USA (IAS-USA) list. ITT-E Resistance Tested through Week 24 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 24 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or met the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA < 50 c/mL) and have confirmed plasma HIV-1 RNA >= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA < 50 c/mL) after Week 8 with last plasma HIV-1 RNA >=400 c/mL.
Measured: Up to Week 24
Number of Participants With Newly-emergent Genotypic Substitutions at Week 48
Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 48 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 48 Snapshot analysis window. The criteria for resistance tested was participant who had virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA < 50 c/mL) and have confirmed plasma HIV-1 RNA >= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA < 50 c/mL) after Week 8 with last plasma HIV-1 RNA >=400 c/mL.
Measured: Up to Week 48
Number of Participants With Newly-emergent Genotypic Substitutions at Week 96
Participants who administered ARV with VF were assessed. Genotypic substitution included assessment of RT substitution, PI substitution and Integrase RAL substitution as per IAS-USA list. ITT-E Resistance Tested through Week 96 population included participants who met the criteria for Resistance testing, and the confirmatory value or value at discontinuation occurred at or before the end of the Week 96 Snapshot analysis window. The criteria for resistance tested was participants with virologic failure or the following criteria a) Participants who achieved viral suppression (plasma HIV-1 RNA < 50 c/mL) and have confirmed plasma HIV-1 RNA >= 400 c/mL at any time during the study. b) Participants who were discontinued before achieving viral suppression (plasma HIV-1 RNA < 50 c/mL) after Week 8 with last plasma HIV-1 RNA >=400 c/mL.
Measured: Up to Week 96
Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA >= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA >=50 copies/mL at any time after prior confirmed suppression to <50 copies/mL OR confirmed >1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was >= 50 copies/mL . The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
Measured: Baseline and up to Week 24
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA >= 50 copies/mL at Week 24 or later or later or virologic rebound defined as confirmed HIV-1 RNA >=50 copies/mL at any time after prior confirmed suppression to <50 copies/mL OR confirmed >1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was >= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
Measured: Baseline and up to Week 48
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 96
Virologic failure is defined clinically as confirmed plasma HIV-1 RNA >= 50 copies/mL at Week 24 or later or virologic rebound defined as confirmed HIV-1 RNA >=50 copies/mL at any time after prior confirmed suppression to <50 copies/mL OR confirmed >1 log10 copies/mL increase in HIV-1 RNA at any time above nadir level where nadir was >= 50 copies/mL. The phenotypic resistance to a drug is defined as a fold change (i.e, ratio of the IC50 of the clinical isolate to the IC50 of the reference strain) greater than the cut-off for reduced susceptibility. Maximum change from Baseline in Temsavir IC50 fold change based on all on-treatment values has been presented. Baseline is defined as the last non-missing value on or before the date of first dose of study treatment and those values are absolute values. Change from Baseline was calculated as value at indicated time point minus Baseline value. Only those participants available at the specified time points were analyzed.
Measured: Baseline and up to Week 96
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2011 (estimated)
- Study start26 Jul 2011
- Primary completion18 Feb 2013
- Study completion12 May 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Infection, Human Immunodeficiency VirusStudies of the same condition, open and under way.
- More trials run by ViiV HealthcareThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 254 participants (actual)
Sponsor and investigators
- Lead sponsor
- ViiV Healthcare
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, ViiV Healthcare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01384734
- Sponsor's protocol ID
- 205889
- Other IDs
- AI438-011
- Status last verified
- Aug 2018
- First submitted
- 23 Jun 2011
- Last updated
- 14 Nov 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OAS, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215-223. doi: 10.3851/IMP3112. Epub 2016 Dec 6.
PubMed 27922453Landry I, Zhu L, Abu Tarif M, Hruska M, Sadler BM, Pitsiu M, Joshi S, Hanna GJ, Lataillade M, Boulton DW, Bertz RJ. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2782-9. doi: 10.1128/AAC.02503-15. Print 2016 May.
PubMed 26902761Lalezari JP, Latiff GH, Brinson C, Echevarria J, Trevino-Perez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, Martins M, Diaconescu IG, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1.
PubMed 26423650Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, Lataillade M, Hanna GJ, Krystal M. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J Antimicrob Chemother. 2014 Mar;69(3):573-81. doi: 10.1093/jac/dkt412. Epub 2013 Oct 14.
PubMed 24128669
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose
- ClinicalTrials.gov ID
- NCT01384734
- Acronym / sponsor ID
- 205889
- Conditions
- Infection, Human Immunodeficiency Virus
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 254 participants (actual)
- Lead sponsor
- ViiV HealthcareIndustry (pharma, biotech, devices)
- Study start
- 26 Jul 2011 (actual)
- Primary completion
- 18 Feb 2013 (actual)
- Study completion
- 12 May 2017 (actual)
- First posted
- 29 Jun 2011 (estimated)
- Results
- Posted 14 Nov 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.
Detailed description
Masking: Double-blind for BMS-6630368 treatment groups until the Week 24 Primary Endpoint analysis, then open label. The reference groups is all open-label.
Arms: 5 (4 BMS-663068 treatment groups and 1 reference group)
Intervention Model: Parallel (with unblinding after the Week 24 primary endpoint analysis)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir | Experimental | Drug: BMS-663068 400 mg, Drug: Raltegravir 400 mg, Drug: Tenofovir 300 mgTreatment Group 1 |
| Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir | Experimental | Drug: BMS-663068 800 mg, Drug: Raltegravir 400 mg, Drug: Tenofovir 300 mgTreatment Group 2 |
| Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir | Experimental | Drug: BMS-663068 600 mg, Drug: Raltegravir 400 mg, Drug: Tenofovir 300 mgTreatment Group 3 |
| Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir | Experimental | Drug: BMS-663068 1200 mg, Drug: Raltegravir 400 mg, Drug: Tenofovir 300 mgTreatment Group 4 |
| Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir | Active comparator | Drug: Raltegravir 400 mg, Drug: Tenofovir 300 mg, Drug: Ritonavir 100 mg, Drug: Atazanavir 300 mgTreatment Group 1 (reference arm) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
- Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
- Screening PHENOSENSE Entry indicating BMS-626529 inhibitory concentration (IC)50 < 0.1 μM
- Cluster of differentiation (CD)4+ T-cell count > 50 cells/mm3
Key exclusion criteria (2 listed)
- History (or evidence at Screening) of genotypic resistance to any component of the study regimen [ Tenofovir Disoproxil Fumarate (TDF), Atazanavir (ATV), Raltegravir (RAL)]
- Certain laboratory and electrocardiogram (ECG) values
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BMS-663068 400 mgTablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose | Drug | Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir |
| BMS-663068 800 mgTablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose | Drug | Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir |
| BMS-663068 600 mgTablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose | Drug | Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir |
| BMS-663068 1200 mgTablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose | Drug | Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir |
| Raltegravir 400 mgTablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose | Drug | Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir, Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir, Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir, Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir, Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir |
| Tenofovir 300 mgTablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose | Drug | Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir, Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir, Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir, Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir, Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir |
| Ritonavir 100 mgTablets, Oral, 100 mg, Once daily, 96 weeks | Drug | Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir |
| Atazanavir 300 mgCapsules, Oral, 300 mg, Once daily, 96 weeks | Drug | Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir |
Primary outcome
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24
Time frame: Week 24
Percentage of participants with plasma HIV 1 RNA < 50 c/mL at Week 24 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to evaluate the antiviral activity. Treatment comparisons were not performed as this was an estimation study. Response rates were tabulated by treatment arm with exact Clopper-Pearson binomial 95 percentage confidence intervals (CI). Virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment within the snapshot window of the visit of interest. Intent-To-Treat-Exposed (ITT-E) Population includes all randomized participants who received at least one dose of study treatment.
Number of Participants With Serious Adverse Events (SAE) and Discontinuation Due to AEs up to Week 24
Time frame: Up to Week 24
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or suspected transmission of an infectious agent via the study drug were categorized as SAE. AEs leading to discontinuation of study therapy were also reported as safety assessment. Safety population included all participants who received at least one dose of study treatment. Summaries of SAEs and AEs leading to discontinuation or withdrawal through Week 24 included AEs with onset on or after the start of study treatment (i.e. study date of first study treatment intake) up to and including the end of the Week 24 visit snapshot window.
15 secondary outcomes
Change From Monotherapy Baseline in log10 HIV RNA of the Monotherapy Period
Time frame: Baseline and up to Day 8 of the monotherapy period
Maximum Decrease From Monotherapy Baseline in log10 Plasma HIV-1 RNA
Time frame: Baseline and up to Day 8 of the monotherapy period
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Day 8 of the Monotherapy Period
Time frame: Up to Day 8 of the monotherapy period
Number of Participants With SAE and Discontinuation Due to AEs During Monotherapy Period
Time frame: Up to Day 8 of the monotherapy period
Change From Monotherapy Baseline in Cluster of Differentiation (CD)4+ and CD8+ T-cell Counts During Monotherapy
Time frame: Baseline and Day 8
Change From Monotherapy Baseline in CD4+ and CD8+ T-cell Proportion During Monotherapy
Time frame: Baseline and Day 8
Percentage of Participants With Plasma HIV-1 RNA < 50 c/mL at Primary Study
Time frame: Weeks 48 and 96
Number of Participants With SAE and Discontinuation Due to AEs During Primary Study
Time frame: Weeks 48 and 96
Change From Baseline in CD4+ T-cell Count
Time frame: Baseline and Weeks 24, 48 and 96
Number of Participants With Newly-emergent Genotypic Substitutions at Week 24
Time frame: Up to Week 24
Number of Participants With Newly-emergent Genotypic Substitutions at Week 48
Time frame: Up to Week 48
Number of Participants With Newly-emergent Genotypic Substitutions at Week 96
Time frame: Up to Week 96
Maximum Change From Baseline in Inhibitory Concentration at 50% (IC50) Fold Change Among Participants With VF at Week 24
Time frame: Baseline and up to Week 24
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 48
Time frame: Baseline and up to Week 48
Change From Baseline in IC50 Fold Change Among Participants With VF at Week 96
Time frame: Baseline and up to Week 96
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 27922453Thompson M, Lalezari JP, Kaplan R, Pinedo Y, Pena OAS, Cahn P, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial. Antivir Ther. 2017;22(3):215-223. doi: 10.3851/IMP3112. Epub 2016 Dec 6.
- Derived from this study: PubMed 26902761Landry I, Zhu L, Abu Tarif M, Hruska M, Sadler BM, Pitsiu M, Joshi S, Hanna GJ, Lataillade M, Boulton DW, Bertz RJ. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2782-9. doi: 10.1128/AAC.02503-15. Print 2016 May.
- Derived from this study: PubMed 26423650Lalezari JP, Latiff GH, Brinson C, Echevarria J, Trevino-Perez S, Bogner JR, Thompson M, Fourie J, Sussmann Pena OA, Mendo Urbina FC, Martins M, Diaconescu IG, Stock DA, Joshi SR, Hanna GJ, Lataillade M; AI438011 study team. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37. doi: 10.1016/S2352-3018(15)00177-0. Epub 2015 Sep 1.
- Derived from this study: PubMed 24128669Zhou N, Nowicka-Sans B, McAuliffe B, Ray N, Eggers B, Fang H, Fan L, Healy M, Langley DR, Hwang C, Lataillade M, Hanna GJ, Krystal M. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J Antimicrob Chemother. 2014 Mar;69(3):573-81. doi: 10.1093/jac/dkt412. Epub 2013 Oct 14.
Related trials for Infection, Human Immunodeficiency Virus
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitation
Promoting Aging and Thriving With HIV
HIV (Human Immunodeficiency Virus), Geriatric
RecruitingObservational study
Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide
HIV (Human Immunodeficiency Virus), Pregnancy
Not yet recruiting
HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
HIV Testing, STI
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
ViiV Healthcare
54 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing BMS-663068 400 mg, BMS-663068 800 mg and BMS-663068 600 mg in people with Infection, Human Immunodeficiency Virus, run by ViiV Healthcare at 54 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 54 sites in United States, Mexico, Peru, Argentina, Germany and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Nov 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) < 50 Copies Per Milliliter (c/mL) at Week 24 (time frame: Week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01384734, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2018.